title: [Treatment regimen for children and adolescents with Hodgkin's disease designed to decrease late complications of radiotherapy].
abstract: Between 1997 to 1999 in 9 centres of the Polish Paediatlic Leukemia/Lymphoma Study Group, 167 children and adolescents (aged 2-19 years) with stage 1 to IV Hodgkin's disease (HD) were treated according to a regimen with a limited use of radiotherapy (RT). All patients received B-DOPA and MVPP chemotherapy. The number of cycles of chemotherapy was adjusted in respective risk groups. In 13 children with stage IA and IIA disease with favourable prognostic factors chemotherapy alone was used. In other patients the dose of RT applied to lymphatic regions was 15-46,4 Gy. In case of a small tumour at presentation and good response to initial chemotherapy the RT dose was 15-16 Gy. In other cases doses of 25-30 Gy were planned. The use of higher doses, particularly exceeding 35 Gy, in eleven patients, was not justified. Among all the 167 patients, three oftliem (1.2%) with advanced disease (Stage III-1V) did not achieve first remission. The 4-year overall survival (OS), relapse free survival (RFS) and event free survival (EPS) were 99%. 93% and 90%, respectively. Relapses occurred in 8 children (first remission lasted for 4-29 (median = 9 months). All 13 children in whom chemotherapy alone was used remain in first remission. In the group of children who received RT in the dose of 15-16 Gy relapse occurred in one child. Our preliminary analysis indicates that limited use of RT in selected cases of HD in children and adolescents did not show worse results of treatment. However, the assessment of possible influence of this regimen on the decreased rate of late complications requires longer follow-up.
authors: Klinika Hematologii i Onkologii Dzieciecej, Polsko-Amerykanski Instytut Pediatrii Collegium Medicum, Uniwersytet Jagielonski, Wielicka 265, 30-663 Krakow, Poland.
authors: W
authors: W
authors: Balwierz
authors: A
authors: A
authors: Moryl-Bujakowska
authors: T
authors: T
authors: Depowska
authors: T
authors: T
authors: Klekawka
authors: R
authors: R
authors: Rokicka-Milewska
authors: B
authors: B
authors: Sopylo
authors: B
authors: B
authors: Kolakowska-Mrozowska
authors: A
authors: A
authors: Chybicka
authors: J
authors: J
authors: Boguslawska-Jaworska
authors: J
authors: J
authors: Pisarek
authors: M
authors: M
authors: Ras
authors: D
authors: D
authors: Sonta-Jakimczyk
authors: A
authors: A
authors: Janik-Moszant
authors: P
authors: P
authors: Kolecki
authors: M
authors: M
authors: Kaczmarek-Kanold
authors: J
authors: J
authors: Kowalczyk
authors: T
authors: T
authors: Odoj
authors: M
authors: M
authors: Matysiak
authors: T
authors: T
authors: Newecka-Samol
authors: A
authors: A
authors: Balcerska
authors: E
authors: E
authors: Adamkiewicz-Drozynska
authors: M
authors: M
authors: Wysocki
authors: A
authors: A
authors: Kurylak
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D012008:Recurrence; D012074:Remission Induction; D012306:Risk; D016019:Survival Analysis; D013997:Time Factors